Viewing Study NCT06615050

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:58 PM
Ignite Modification Date: 2025-12-29 @ 12:34 AM
Study NCT ID: NCT06615050
Status: RECRUITING
Last Update Posted: 2025-12-16
First Post: 2024-09-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Sponsor: Incyte Corporation
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Graft-versus-host Disease (GVHD) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Graft-versus-host Disease (GVHD) View
None Chronic GvHD (cGvHD) View
None steroid-refractory View
None ruxolitinib View
None Janus kinase inhibitor View